AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01164150 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 45 Gy/25 fractions
Description: Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy
Study NCT01688622 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 3months Exercise
Description: training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
Study NCT00014612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary lymph node dissection
Study NCT00014612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymphoscintigraphy
Study NCT00014612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphoscintigraphy
Study NCT00014612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Study NCT00014612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT00014612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)
Description: Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentacel™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediarix™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: Two oral doses in primary epoch at 2 and 4 months of age
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Two oral doses in primary epoch at 2 and 4 months of age
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™
Description: One dose in the booster epoch at 15-18 months of age as intramuscular injection
Study NCT01000974 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™
Description: One dose in the booster epoch at 15-18 months of age as intramuscular injection
Study NCT02651025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Program
Description: During the first week of training will be conducted two sets of 10 repetitions, and from the second week of training until the twelfth will be performed three sets of 10 repetitions. The work rate will set to the tolerance of each patient as established by his/her inability to maintain Borg ratings for dyspnea and effort (10-point category-ratio Borg scale) scores between 4 and 6.
Study NCT00536653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide and Calcium/ Vitamin D supplementation
Description: Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily
Study NCT00536653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation
Description: 3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily
Study NCT00536653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH agonists (Goserelin acetate)
Description: 3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)
Study NCT01364337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: DASH diet: A diet rich in whole grain, fruit and vegetable, low-fat dairy products, white meat and nuts; and lower of total fat and saturated fat.
Study NCT01364337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lower carbohydrate DASH diet
Description: lower carbohydrate DASH diet: A DASH diet with lower carbohydrate percentage
Study NCT01299051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Steps to Health
Description: Steps to Health (STH): The STH curriculum is a 12-month educational program targeting obese employees for healthy lifestyle changes for weight loss. The program includes:~* Face-to-face visit with counselor during Month 1 to set specific health goals.~* Telephone counseling at 6 and 12 months, coupled with biometric feedback sessions.~* Monthly generic health education materials sent via e-mail.~* Incentives (up to 1,000 STH dollars \[$100\]) to take part in the program assessments.
Study NCT01299051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steps to Health Plus!
Description: The STH+ intervention is an intensive 12-month behavioral intervention targeting obese employees. It is stage-based and works with the participant at his/her level of readiness to change using counseling based on motivational interviewing. STH+ includes:~* Face-to-face visit with counselor at Month 1~* Meeting with exercise physiologist in Month 2~* Monthly counseling sessions (in-person in Months 3, 6, 9 and 12, others via telephone)~* Meeting with exercise physiologist during Month 5~* Quarterly biometric feedback (Months 3, 6, 9, and 12)~* Incentives (up to 1,000 STH dollars \[$100\]) to take part in the program assessments.
Study NCT01445041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood
Description: Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 1 infusion of their own volume reduced cord blood cells. The dose for each infusion is 5x10e7 cells/kg.
Study NCT01445041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood
Description: Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 3 infusions of their own volume reduced cord blood cells. The first infusion will be a fresh, volume-reduced infusion and the subsequent infusions will be thawed and washed infusions. The dose for each infusion is 5x10e7 cells/kg.
Study NCT02716792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
Study NCT02716792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
Study NCT01289548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischaemic preconditioning
Description: Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
Study NCT05242302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve transfer
Description: the anterior interosseous nerve will be used as a donor to reinnervation the injured ulnar nerve.
Study NCT05242302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nerve transfer
Description: the anterior interosseous nerve will be used as a donor to reinnervation the injured ulnar nerve.
Study NCT01751321 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin, placebo
Description: sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
Study NCT03975504 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Low Dose Computed Tomography
Description: LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
Study NCT03975504 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: artificial intelligence (AI)
Description: AI was performed in high-risk individuals recruitment and lung nodules management
Study NCT03975504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: autofluorescence imaging (AFI)
Description: AFI applied in screening of centrally located SCC.
Study NCT01898052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single anaesthetic drug
Description: inject periarticular tissue of the knee after implantation
Study NCT01898052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multimodal drug injection
Description: inject periarticular tissue of the knee
Study NCT03455712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gestational Weight Gain Card
Description: The Gestational Weight Gain Card is designed to be an educational and weight gain tracking tool. Study subjects will be highly encouraged to use the GWG card to gain both important clinical information and to document weight measurements throughout their pregnancy.
Study NCT01570140 — intervention group
Intervention type: BEHAVIORAL
Intervention: Web portal
Description: This study investigates the effects of the voluntarily use of a webportal and its educational content.
Study NCT02677415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous anesthetics
Study NCT02677415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: local anesthesia
Study NCT02677415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Controlled ventilation
Study NCT02677415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spontaneous breathing
Study NCT03752476 — intervention group
Intervention type: PROCEDURE
Intervention: number of Beta lactam class prescription for the same infection
Description: Each number of Beta lactam prescription without interruption are compared
Study NCT01973686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study NCT02050139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-cysteine
Study NCT02050139 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03613714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: At-home Blood Pressure Monitoring
Description: Participants will use over-the-counter digital monitor to measure blood pressure and pulse rate at home. Automatically averages the last 3 readings taken over 10 minutes.
Study NCT02089802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study NCT00416819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00416819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00416819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00416819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Study NCT00416819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00416819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00416819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT02508376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AP10-602
Description: AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57. The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.
Study NCT02508376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57
Study NCT02508376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93
Description: ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
Study NCT03258645 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Description: Oral anticoagulant (NOAC) thrombin inhibitor
Study NCT01772927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Parenteral Nutrition
Description: Protein and energy intakes
Study NCT04195724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mNGS for pathogen detection
Description: mNGS for pathogen detection and metabonomics (ascites, fecal,venous blood from superior mesenteric vein, hepatic vein and peripheral vein, respectively)
Study NCT00078403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 mcg PEG-IFN subcutaneously
Study NCT00078403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: One tablet or capsule containing ribavirin 200 mg
Study NCT02702843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with Xenon light
Description: Standard laparoscopic cholecystectomy with white light
Study NCT02702843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy with Xenon light
Description: Standard laparoscopic cholecystectomy with white light
Study NCT02702843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (fluorescent cholangiography)
Description: Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
Study NCT03002545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium citrate
Study NCT03002545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02171429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
Study NCT02171429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adalimumab Placebo
Description: Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
Study NCT02171429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab Placebo
Description: Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
Study NCT02171429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
Study NCT02171429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Etrolizumab Placebo
Description: Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
Study NCT02171429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Etrolizumab Placebo
Description: Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
Study NCT02458560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards CENTERA Self-Expanding Transcatheter Heart Valve
Description: The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
Study NCT02100280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deep block
Description: sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
Study NCT00977912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Description: one capsule containing probiotics per day added to milk
Study NCT00977912 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk containing placebo
Description: one capsule containing placebo per day added to milk
Study NCT01668056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovulation induction with choriogonadotropin alfa
Description: Administration of 250 micrograms of choriogonadotropin alfa subcutaneously when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
Study NCT01668056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration of the dominant follicle
Description: Aspiration of all follicles greater than 10mm in mean diameter when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Aspiration will be guided by transvaginal ultrasound. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
Study NCT01668056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional flexible GnRH antagonist protocol of ovarian stimulation for in vitro fertilization, with gonadotropin star at the third day of a natural menstrual cycle.
Study NCT03141190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction - modified
Description: already described
Study NCT03141190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active listening and reading
Description: group reading, listening and discussion of articles pertaining to the development and experience of the surgical personality
Study NCT01675492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: Surgeons will perform wavefront-guided LASIK based upon measurements obtained with the iDesign System
Study NCT03055247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
Study NCT03055247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myelostim
Description: Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
Study NCT03055247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mozobil
Description: Mozobil (Plerixafor): 0,24 mg/kg daily. When CD34+ are ≥ 10 /μL Plerixafor will be administered subcutaneously from the next day (or from day 24 if CD34+ are \< 10 /μL) to the day of the last LP.
Study NCT02801825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.
Description: Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.
Study NCT02801825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided out-of-plane femoral artery cannulation.
Description: Real-time ultrasound-guided out-of-plane femoral artery cannulation.
Study NCT03145753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV/HCV Education plus Testing
Description: Education included a half day educational program and the provision of supporting materials to enhance HIV testing, such as a clinical decision algorithm to perform HIV test and clinical remainders to help meet with the current Spanish Early Diagnosis HIV Testing Recommendations. Half day educational program, to promote early diagnosis of HIV, HCV, in a Primary Care Health Area.To Improve knowledge and current trends in the prevention, diagnosis and management of HIV infection among non health professionals specialists in infectious diseases.DRIVE 03 program will offer rapid HIV tests, and testing staff to conduct all study procedures.The study activities will be carried out by the trained testing staff.
Study NCT03145753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIV/HCV Education
Description: Only education and support will be provided in this arm